Acute Lymphoblastic Leukemia(T-ALL)-08

Yesheng from Fujian said, "If I had known about CAR-T at Ludaopei, I would have come earlier."

In September 2017, Yesheng developed facial rashes, which gradually spread and merged into patches. By February 28, 2018, bone marrow examination confirmed "acute T-cell lymphoblastic leukemia" after multiple courses of chemotherapy, with intermittent negative residual checks. All medications were stopped in June 2019.

In May 2021, Yesheng presented with masses in the oral-pharyngeal region and enlarged neck lymph nodes. Bone marrow re-examination confirmed a complete relapse of leukemia. On May 28, Yesheng was transferred to the Second Hematology Department of Ludaopei Hospital for admission. After comprehensive examinations, the diagnosis was revised to "acute leukemia (T/myeloid biphenotypic)."

One cycle of chemotherapy did not induce remission in the bone marrow. On July 27, Yesheng received CD7 CAR-T cell infusion, followed by chemotherapy combined with autologous CD7 CAR-T cell therapy. Fifteen days after infusion, bone marrow examination showed negative residual disease, with a grade 1 cytokine release syndrome (CRS) reaction and no central nervous system adverse reactions.